Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer
The purpose of this study is to evaluate the impact of the addition of cisplatin to gemcitabine in the treatment of patients with inoperable advanced pancreatic cancer.
Pancreatic Cancer
DRUG: gemcitabine|DRUG: cisplatin
overall survival, 9 months
clinical benefit response, baseline and at end of every cycle of therapy|quality of life, baseline and at end of every cycle of therapy|objective response, after 7 weeks of therapy|time to progression, 6 months
The purpose of this study is to evaluate the impact of the addition of cisplatin to gemcitabine in the treatment of patients with inoperable advanced pancreatic cancer.